Ingrid Boere

Ingrid Boere is a researcher in the Department of Medical Oncology at Erasmus MC, Faculty of Medicine. Her work is centered on gynecologic cancers, particularly ovarian, cervical, and endometrial cancers, with a focus on treatment optimization, biomarker research, and clinical trial design.

Her research interests include:

• Medical and gynecologic oncology
• Targeted therapies such as PARP inhibitors (olaparib) and immunotherapies (dostarlimab)
• Pharmacokinetics and chemotherapy optimization
• Biobanking and translational research infrastructure
• Patient quality of life and survival outcomes

The recent articles highlight her involvement in key clinical trials and biobanking initiatives. Her work spans phase III randomized trials, non-inferiority studies, and infrastructure development for collaborative cancer research, with strong emphasis on data sharing, biomarker-driven therapy, and improving outcomes in rare gynecological malignancies.

Scientific contributions include:

• PROACTIVE-B trial on olaparib boosting
• ENGOT-EN6-NSGO/GOG-3031/RUBY immunotherapy trial
• Nationwide Dutch ovarian cancer biobank evaluation
• IT infrastructure for multicenter biobanking

Ingrid Boere actively collaborates with national and international research consortia, contributing to large-scale clinical and translational studies. She participates in multidisciplinary teams focused on advancing precision oncology and building sustainable research infrastructures. While no formal advising or grant information is available, her co-leadership roles in major studies suggest significant research leadership.